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The Global Fund in China: success beyond the numbers
In June, 2014, the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria completed its support for 
operations in China.1 The 10-year partnership between 
China and the Fund measurably improved China’s 
management of the three diseases, but it also created 
beneﬁ ts that extend far beyond the metrics usually 
used to assess public health programmes. These 
beneﬁ ts include deeper engagement with civil society 
organisations, stronger public health systems, and the 
implementation of innovative approaches for disease 
management. As China celebrates these achievements, 
it must also devise a roadmap for continuing its record 
of success, now that the Fund has left. 
China’s relationship with the Global Fund began shortly 
before the 2003 severe acute respiratory syndrome 
epidemic, an event that proved the importance of 
containing public health threats that could undermine 
the country’s economic growth. Successful pilot 
programmes have shown the eﬀ ectiveness of various 
interventions against tuberculosis, malaria, and 
HIV/AIDS, and demonstrated the potential for scaling up 
those programmes in a way that would create a greater 
impression. In fact, it was the very potential large-scale 
interventions and strategic public health programming 
that made China and the Fund such natural partners. The 
results have been impressive.
Access to quality diagnosis and treatment of multidrug-
resistant tuberculosis (MDR-TB) expanded from just 
two pilot projects in 2006 in two provinces to 92 sites 
in 30 provinces in 2013. China has also expanded access 
to innovative rapid diagnosis for MDR-TB in more than 
900 counties across the country. And, by the end of June, 
2014, more than 9000 patients had started treatment for 
MDR-TB (unpublished data). 
Extraordinary progress was made towards the 
elimination of malaria. In 2002, the objective was to 
control malaria’s spread; by 2020, the goal will be to 
eliminate local transmission of the disease entirely.2 
Between 2002 and 2012, the number of Chinese 
provinces reporting domestic cases of malaria has 
plummeted from 24 to ﬁ ve, and the number of reported 
malaria cases decreased from 100 106 cases and 
48 deaths in 2005 to 4498 cases and 33 deaths in 2011.3
Finally, China’s rate of HIV infection has been stabilised 
at 0·06%; between 2005 and 2012, the number of 
patients receiving antiretroviral therapy increased from 
19 282 in 2005 to 176 655. HIV prevention outreach 
services achieved 81% coverage in commercial sex 
workers and 77% in men who have sex with men (MSM) 
by 2011. Harm reduction interventions in people who 
inject drugs have brought about substantial reductions 
in HIV incidence (from 0·54% to 0·31%) and prevalence 
(from 9·3% to 6·4%) over 2009–11 (unpublished).
Important though they are, numbers alone do not 
tell the whole story. Engagement with the Global Fund 
has changed China’s fundamental approach to these 
three diseases, resulting in many gains that are hard 
to quantify but nevertheless invaluable. The ﬁ rst is a 
change in mindset. The way China’s leaders think about 
development has progressed, making the public health 
system more transparent, open, and accountable. This 
quantum advance in governance derived partly from 
procedural and reporting requirements that came 
with China’s alliance to the Global Fund. The Chinese 
Government coﬁ nanced the Global Fund programme, 
a move that transformed China from an aid recipient 
into a full and active partner. Such a collaborative 
arrangement meant that all costs and other procedural 
details were clearly and publicly allocated, and that all 
programmes were audited, infusing the system with 
international standards of transparency. 
Another beneﬁ t has been the development of a more 
coherent public health strategy. The Global Fund seeks 
to back programmes that show a uniﬁ ed strategy, 
rather than a series of individual projects. After several 
years of collaboration with the Fund, China became 
one of the ﬁ rst countries to seek support for a national 
strategy aimed at controlling HIV/AIDS, tuberculosis, and 
malaria. The result has been a greater integration and, 
ultimately, a more strategic and coherent programme of 
interventions. 
The China and the Global Fund partnership also 
used a health system approach by assisting local 
manufacturers through the WHO prequaliﬁ cation 
process to provide quality-assured tuberculosis, HIV, and 
malaria drugs. Collaboration also supported State Food 
and Drug Administration (now China Food and Drug 
Administration) alignment with Good Manufacturing 
Practices, Pharmacopeia, and laboratory testing 
international standards.
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Partnership with the Global Fund also introduced a 
dose of pluralism into China’s management of the three 
diseases. In accordance with the Fund’s procedures, 
China established a Country Coordinating Mechanism, a 
platform for coordinating several stakeholder inputs and 
mobilising support. When deciding whether to back a 
particular public health eﬀ ort, the Fund looks for evidence 
of involvement by civil society, usually manifested by the 
presence of non-governmental organisations (NGOs). 
The Country Coordinating Mechanism requirements 
spell out criteria for stakeholder involvement that 
includes a balance in the representation of the diﬀ erent 
stakeholder groups, and a transparent process of 
selection. On the basis of these criteria, UNAIDS and 
WHO, in close collaboration with the chair and secretariat 
of the Country Coordinating Mechanism, supported the 
NGO constituency to develop bylaws and rules of order, 
following Robert’s Rules of Order,4 and to undertake 
a nationwide transparent election to establish which 
groups would represent the sector. Such a democratic 
process had previously not been applied to determine 
stakeholder engagement and might serve as a model 
beyond the Global Fund governance structure in China. 
Now that its partnership with the Fund has ended, 
China is in a strong position to move into the next 
phase of managing the three diseases. Despite the 
great strides made in controlling tuberculosis, China 
still counts 1 million new cases a year, including roughly 
54 000 cases of MDR-TB.5 As with any public health 
disease, access to diagnosis and treatment should be 
free of charge to patients. Currently, MDR-TB treatment 
costs about 50 000 RMB (about US$8025) per year. 
Unless the government covers the cost, while making 
a simultaneous commitment to improving treatment 
quality, China might undergo a major public health 
crisis that could set back its developmental progress by 
20 years or more. 
Malaria is in the elimination phase, and its reach is 
much more restricted than that of tuberculosis. But 
malaria travels across borders, so China must collaborate 
with its neighbours. This collaboration will require 
decisive action in managing critical issues related 
to the cross-border spread of artemisinin-resistant 
malaria, and to the mobile population of migrants 
who become infected in Cambodia or Laos and then 
enter China.6 Although daunting, as with other public 
health concerns, these challenges present China with an 
opportunity to take a more active role in public health at 
a regional and global level.7
China has decided to take over the Global Fund’s 
ﬁ nancial commitments on HIV/AIDS. The task now is 
to establish further collaboration between grassroots 
organisations and the Chinese Government. Hard-to-
reach populations are most eﬀ ectively targeted through 
community programmes, since many such populations, 
such as intravenous drug users, MSM, and commercial 
sex workers will not go to regular hospitals. Now that 
China has committed to funding continued treatment 
of HIV/AIDS, it must make a parallel commitment 
to supporting at-risk groups and the civil society 
organisations that represent them. Although outreach 
to at-risk populations is a challenge everywhere in the 
world, China’s public health system in particular must 
make a special eﬀ ort to connect with these groups.8–10
Each of the three diseases presents its own unique 
challenges: HIV/AIDS, with its need to manage social 
and other intimate behaviours; malaria, now in the 
elimination phase but still casting its shadow across 
China’s borders; and tuberculosis, imposing an un-
acceptably heavy disease burden on the country. With the 
Global Fund gone, China must integrate the management 
of these three diseases into its broader programme of 
health reform. Key indicators or measures of progress 
will include better governance, more transparency, and 
greater accountability. It is up to China’s leaders to pick up 
where the Global Fund left oﬀ , supporting these eﬀ orts 
ﬁ nancially and with an ongoing commitment to good 
governance. 
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